{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["On September 18, 2026, Amneal announced FDA approval and the immediate U.S. launch of generic lanreotide injection, a 120 mg prefilled syringe competing with Ipsen’s Somatuline Depot.", "The lanreotide product received Competitive Generic Therapy designation, which can support faster market entry and potentially improve commercial economics.", "Recent FDA approval and launch of a high-value generic drug could boost revenue.", "Analyst upgrades and price target increases show strong Wall Street support.", "FDA approval and immediate launch of generic lanreotide targets a nearly $1 billion U.S. market, giving Amneal a real revenue opportunity."], "company_name": "Amneal Pharmaceuticals, Inc.", "conviction": "low", "data_quality": 0.875, "date": "2026-09-22", "favorable_models_count": 1, "final_confidence": 0.6277001852749388, "final_score": 74.152, "generated_at": "2026-09-22T07:30:00.006272-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 80.38, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The FDA approval catalyst was announced several days ago, so some of the expected upside may already be reflected in the stock price.", "AMRX is technically extended, with an RSI around 70, increasing the risk of profit-taking or a sharp pullback in the next session.", "The stock is technically overbought after a rapid price surge.", "Momentum may fade as the FDA news is now several days old.", "The stock is technically overbought with an RSI above 70 after a 17% run in just five days, making a pullback or pause likely."], "shortfalls": ["Only 1 of the 2 bullish votes we want"], "status": "signal", "summary": "The main next-session catalyst is continued reaction to Amneal’s FDA approval and immediate launch of generic lanreotide, announced September 18 and driving strong trading into September 21-22. The commercial opportunity is significant, and analyst support plus elevated volume favor a bullish bias, but the catalyst is no longer brand new and the stock is technically overbought after a rapid advance.", "ticker": "AMRX", "timezone": "Europe/Zurich", "watchlist": [{"company_name": "Aurora Innovation, Inc.", "conviction": "high", "favorable_models_count": 3, "final_confidence": 0.6858492834453386, "final_score": 72.01266666666666, "quantitative_score": 65.24, "shortfalls": [], "summary": "Aurora Innovation (AUR) enters the next U.S. session with a cluster of bullish catalysts: fresh detailed coverage of its plan to ramp to roughly 20 driverless trucks per week using cheaper second‑generation hardware, a high‑margin driver‑as‑a‑service pivot, multiple supportive analyst actions (including reiterated Overweight ratings and higher price targets from major firms), and an imminent Analyst & Investor Day on September 23 that event‑driven traders may front‑run. These factors, combined with elevated recent trading activity, point to a bullish setup for the next session, though the stock’s near‑overbought technicals and the risk of disappointment or profit‑taking around the event could add volatility.", "ticker": "AUR"}]}